Attached files
| file | filename |
|---|---|
| EX-99.01 - Inspyr Therapeutics, Inc. | v194541_ex99-01.htm |
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): August 18, 2010 (August 12,
2010)
GENSPERA,
INC.
(Exact
name of registrant as specified in Charter)
|
Delaware
|
0001421204
|
20-0438951
|
||
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
File No.)
|
(IRS
Employee Identification No.)
|
2511
N Loop 1604 W, Suite 204
San
Antonio, TX 78258
(Address
of Principal Executive Offices)
210-479-8112
(Issuer
Telephone number)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.
On August
12, 2010, John M. Farah, Jr., Ph.D. notified GenSpera, Inc. (“Company”) of his
voluntary resignation as a director due to policy changes at his current
employer with regard to outside directorships. Dr. Farah’s
resignation is effective as of August 16, 2010.
On August
16, 2010, the Company appointed Bo Jesper Hansen, MD, Ph.D. to its board of
directors. Dr. Hansen will also serve on the Company’s: Audit, Nominating and Corporate
Governance, and Leadership Development and Compensation
committees. As compensation for his service on the board and
related committees, Dr. Hansen will be entitled to compensation pursuant to the
Company’s non-executive board compensation
policy. A copy of the press release announcing Dr. Hansen’s
appointment is attached to this report as Exhibit 99.01.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report on Form 8-K to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated:
August 18, 2010
|
GenSpera,
Inc.
|
|||
|
|
By:
|
GenSpera,
Inc.
|
|
|
Craig
Dionne
|
|||
|
Chief
Executive Officer
|
|||
INDEX
OF EXHIBITS
|
|
|
Incorporated
by Reference
|
||||||||||
|
Exhibit
No.
|
Description
|
Filed
Herewith
|
Form
|
Exhibit
No.
|
File No.
|
Filing Date
|
||||||
|
99.01
|
Press
Release dated August 17, 2010
|
*
|
||||||||||